Upload
phamkhue
View
214
Download
0
Embed Size (px)
Citation preview
ERR
T
Q
Q
hw
Q
dt
Q
ptp
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:371
xam 2: Allopurinol to Prevent Pancreatitis After ERCP: Aandomized Placebo-Controlled Trial
omagnuolo, et al, Authors
est ID No.: 0055 Contact hours: 1.0 Expiration Date: April 30, 2009
uestion 1:
b
The most common complication of ERCP is?d
uestion 2:
b
d
uestion 3:
b
d
uestion 4:
ancreatitis except:
b
d
a) Perforation) Pancreatitis
c) Bleeding
) DeathAn attractive property of allopuriol, a xanthine oxidase in-ibitor for the prevention of post-ERCP pancreatitis, includeshich one of the following:
a) Antioxidant and anti-apoptotic properties in humans) High oral bioavailability and long half life
c) Inexpensive) B and c
e) All of the above
To date, which intervention has been shown to effectivelyecrease the rate of post-ERCP pancreatitis in high risk pa-ients?
a) NSAIDS) Protease inhibitors such as gabexate
c) Octreotide
) Pancreatic stentsIn this trial of allopurinol versus placebo in the prevention ofost-ERCP pancreatitis, the logistic regression analysis showedhat all of the following are significant predictors of post-ERCP
a) Previous post-ERCP pancreatitis) Pancreatic injection
c) Pancreatic endotherpay
) Pancreatic stent placement